Technology - Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments

Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments

A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites.


Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design generally follows a “trial and error” approach using a limited number nanoparticle types to fit a variety of drug molecules that exhibit substantial chemical variation. This approach results in suboptimal nano-formulations with compromised efficiency for in vivo drug delivery and decreased probability of successful clinical translation. In contrast, the suite of innovations described herein offer a customized nanocarrier platform with the capability of structure-based design and systematic optimization to bridge the gap for nanomedicine in clinical translation.

Technology Overview:

This innovative technology portfolio from Upstate Medical University provides multiple chemical formulations of telodendrimer nanoparticles made from biocompatible polyethylene glycol, amino acids, and natural compounds. The resulting nanoparticles results in the biocompatible and effective delivery of various therapeutic drugs for targeted disease treatments. Telodendrimer refers to a linear-dendritic copolymer, containing a hydrophilic segment (i.e., PEG or poly/oligo zwitterionic moieties) and one or more dendritic domain with the peripheries covalently conjugated with well-defined chemical moieties selected based on the affinities specifically to the drug molecule to be delivered. Such end groups are selected based on the chemical structure of the chosen therapeutic drug and can be optimized via a systematic combinatorial approach. Drugs that can be sequestered in the customized nanocarriers or linked to the conjugates include, but are not limited to, anticancer drugs: taxanes, Doxorubicin, Platinum drugs, topoisomerase II inhibitors, topoisomerase I inhibitors, tubulin interacting agents, hormonal agents, thymidylate synthase inhibitors, anti-metabolites, alkylating agents, aromatase inhibitors, and antibiotics: e.g. polymyxin, gentamycin, tetracycline drugs, amphotericin, and immune-modulating drugs: methotrexate, dexamethasone, curcumin, tetracycline and derivatives, etc.


  • Stable drug formulations with small nanoparticle sizes (20-30 nm);
  • In vitro and in vivo extended half-life stability;
  • Efficient disease targeting drug delivery;
  • Capability for intracellular delivery;
  • Capability for encapsulating high amounts of drug molecules (10%-100% of drug/nanoparticles by weight);
  • The ability to protect bioactivity with reduced toxicity of current cancer treatments;
  • Well-defined structure for reproducibility; and
  • Provides a systematic approach for nanocarrier optimization based on drug structure to meet FDA regulations and thereby improve potential for clinical translation.


  • Drug Delivery for hyperproliferative disorders including cancer
  • Delivery of antibiotics for infectious disease
  • Drug delivery for other disorders including inflammatory or allergic diseases, autoimmune diseases, graft rejection and other diseases where undesired inflammatory responses need to be inhibited

Intellectual Property Summary:

Patent Information: